Literature DB >> 12479956

Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice.

Mohammad Reza Zarrindast1, Nasrin Faraji, Parvin Rostami, Hedayat Sahraei, Hassan Ghoshouni.   

Abstract

The acquisition of morphine and nicotine conditioned place preference (CPP) and cross-tolerance between the response of two drugs was studied in mice. A biased CPP paradigm was used to study the effect of the agents. Morphine (5 mg/kg) and nicotine (1 mg/kg) induced CPP. Naloxone (0.5, 1 and 2 mg/kg), but not mecamylamine (0.025, 0.05 and 0.1 mg/kg), induced conditioned place aversion (CPA). Both antagonists reversed CPP induced by morphine and nicotine. Administration of one daily dose of morphine (12.5, 25 or 50 mg/kg) for 3 days or nicotine (0.5, 1 or 2 mg/kg) three times a day for 12 days, in order to develop tolerance to the drugs, reduced the conditioning induced by morphine (5 mg/kg) or nicotine (1 mg/kg). CPA-induced by naloxone was reduced in animals, which were rendered tolerant to morphine (50 mg/kg) or nicotine (2 mg/kg). Mecamylamine, however, which did not induce any response in the nontolerant mice, elicited CPP in the tolerant animals. It is concluded that there may be a cross-tolerance between morphine- and nicotine-induced CPP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12479956     DOI: 10.1016/s0091-3057(02)01002-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  22 in total

Review 1.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

2.  Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats.

Authors:  Xiu Liu; Matthew I Palmatier; Anthony R Caggiula; Alan F Sved; Eric C Donny; Maysa Gharib; Sheri Booth
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

Review 3.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

4.  Reversal effect of intra-central amygdala microinjection of L-arginine on place aversion induced by naloxone in morphine conditioned rats.

Authors:  Sara Karimi; Manizheh Karami; Hedayat Sahraei; Mahnaz Rahimpour
Journal:  Iran Biomed J       Date:  2011

5.  Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers.

Authors:  Daniel J O Roche; Lara A Ray; Megan M Yardley; Andrea C King
Journal:  Curr Addict Rep       Date:  2016-02-03

Review 6.  Interactions between nicotine and drugs of abuse: a review of preclinical findings.

Authors:  Stephen J Kohut
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-02       Impact factor: 3.829

7.  Interactions between morphine, scopolamine and nicotine: schedule-controlled responding in rats.

Authors:  Xinwang Li; Jun-Xu Li; Charles P France
Journal:  Pharmacol Biochem Behav       Date:  2010-04-24       Impact factor: 3.533

8.  The use-dependent, nicotinic antagonist BTMPS reduces the adverse consequences of morphine self-administration in rats in an abstinence model of drug seeking.

Authors:  Brandon J Hall; Laura S Pearson; Alvin V Terry; Jerry J Buccafusco
Journal:  Neuropharmacology       Date:  2011-05-30       Impact factor: 5.250

9.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

Review 10.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.